Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Total Occlusion Study of Canada (TOSCA-2) Trial
Harvard Clinical Research Institute, Boston, US
The American College of Cardiology Presented by Dr. Adnan Kastrati
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Presented by Dr. Leif Thuesen
TAXUS II and IV: two-year follow-up
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
American College of Cardiology Presented by Dr. Stephan Windecker
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
REALITY: 8 month results
Presented at ACC 2003 Late Breaking Clinical Trials
Published in the European Heart Journal
The American College of Cardiology Presented by Dr. Raimund Erbel
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Drug-eluting stents for in-stent restenosis
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Atlantic Cardiovascular Patient Outcomes Research Team
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial SESAMI Trial Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Maurizio Menichelli

SESAMI Trial: Background The goal of the trial was to evaluate primary/rescue percutaneous coronary intervention (PCI) using a sirolimus-eluting stent compared with a bare metal stent among patients with acute myocardial infarction. Presented at EuroPCR May 2006

SESAMI Trial: Study Design 320 patients with acute myocardial infarction to be treated with primary or rescue angioplasty without left main disease, saphenous vein grafts, and cardiogenic shock. Randomized. 19% female, mean age 61 years, follow-up 1 year Primary or rescue angioplasty with sirolimus-eluting stent n=160 Primary or rescue angioplasty with bare metal stent n=160 One year angiographic follow up n=166 Primary Endpoint: Angiographic binary restenosis at one year Secondary Endpoint: One year target lesion revascularization (TLR), target vessel revascularization (TVR), target lesion vessel failure (TVF) and major adverse cardiac events (MACE) Presented at EuroPCR May 2006

SESAMI Trial: Baseline Characteristics Baseline characteristics were balanced between groups, with primary PCI performed in 82% of patients and rescue PCI in 18% of patients. In approximately half of the patients, the infarct–related artery was the left anterior descending artery. In the majority of patients, Abciximab was used in either the emergency room or the cath lab. Post-procedural TIMI grade 3 flow was present in 95% of patients. Presented at EuroPCR May 2006

SESAMI Trial: Primary Endpoint One year binary restenosis p<0.05 The primary endpoint of one year binary restenosis on angiography occurred less often in the sirolimus-eluting stent group vs. the bare metal stent group (9.3% vs. 21.3%, relative risk reduction [RRR] 56%, p<0.05). Likewise, clinically driven restenosis was also lower in the sirolimus-eluting stent group (5.6% vs. 17.2%, RRR 64%, p<0.05). Incidence Presented at EuroPCR May 2006

SESAMI Trial: Secondary Endpoints (all p<0.05) Among the secondary endpoints, the sirolimus-eluting stent group had lower rates of TLR (4.3% vs. 11.2%), TVR (5% vs. 13.1%), MACE (6.8% vs. 16.8%) and TVF 8.7% vs. 18.7). There was no difference in acute thrombosis (0.6%), or acute + subacute thrombosis (3.1% vs. 3.7%). Rate Presented at EuroPCR May 2006

SESAMI Trial: Summary Among patients with acute myocardial infarction undergoing primary or rescue PCI, use of sirolimus-eluting stent was associated with a reduction in binary restenosis at one year compared with use of a bare metal stent. Results of the present single center trial are similar to those seen in the multi-center TYPHOON trial, which showed a reduction in target vessel failure at one year with sirolimus-eluting stents compared with bare metal stents in PCI for acute MI, driven primarily by a reduction in TLR. The PASSION trial, however, did not demonstrate a reduction in TLR with paclitaxel-eluting stents over bare metal stents among STEMI patients. A cost-effectiveness analysis from the present trial is underway. Presented at EuroPCR May 2006